M2I-1,
312271-03-7,
MLS000572003,
SMR000194022,
5-[[4-[bis(2-methylpropyl)amino]-3-nitrophenyl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione,
5-[4-(diisobutylamino)-3-nitrobenzylidene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione,
6063-97-4,
AC1METFS,
MLS003905101,
M2I1,
Mad2 inhibitor-1 (M2I-1),
CHEMBL1571889,
BDBM48705,
cid_2883762,
DTXSID00387207,
HMS2507P14,
BCP18837,
EX-A1984,
ZINC4180848,
STK753645,
AKOS001706294,
CS-5670,
MCULE-8543479456,
HY-100341,
A1115/0052415,
5-(4-(diisobutylamino)-3-nitrobenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione,
5-[4-(diisobutylamino)-3-nitro-benzylidene]-2-thioxo-hexahydropyrimidine-4,6-quinone,
5-({4-[Bis(2-methylpropyl)amino]-3-nitrophenyl}methylidene)-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione,
5-[[4-[bis(2-methylpropyl)amino]-3-nitro-phenyl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione,
5-{4-[bis(2-methylpropyl)amino]-3-nitrobenzylidene}-2-thioxodihydropyrimidine-4,6(1H,5H)-dione,
CID2883762,